2021 REQUEST FOR PROPOSALS – Global Blood Therapeutics, Inc. (GBT)- Externally Sponsored Research (ESR) Program

What is it?
The GBT ESR program provides qualified applicants an opportunity to submit requests for research grant funding and/or drug supply from GBT in the areas of interest that provide deeper insights into our medicines, improve patient care, and advance sickle cell disease-related research. This request for proposals (RFP) will focus on two specific areas of research interest for voxelotor.

This program is seeking interested qualified applicants to submit proposals for consideration where they work collaboratively with GBT, or independently, to execute their research. GBT may provide support to the individual Sponsor-Investigator and/or his or her institution, in each case, as provided and documented in the applicable research agreement. For externally sponsored research (ESCR), GBT may provide support for activities such as proposal and/or protocol development, data analysis and interpretation, interactions with regulatory authorities (excluding filing activities, such as direct submission of regulatory package to local authority), and authorship/publication.

The ESR RFP submissions are due end of business (8 pm EST/5 pm PST) on September 30, 2021.

What are the Areas of Focus for this RFP?
Research must align to one or more of the following areas of interest related to voxelotor:

1. **Safety, tolerability and impact of voxelotor in SCD patients with severe renal impairment (estimated glomerular filtration rate [eGFR] of < 30 mL/min/1.732) or are on chronic dialysis)**
2. **Characterize the outcomes and impact of voxelotor on depression and mood in SCD patients using validated instruments and/or psychological evaluation**

Available Support

- **Total funding available by GBT for all research funded under this RFP is ~$500,000.** The number of funding requests awarded will depend on the applications received, in accordance with the allotted budget.
- Applicants must provide a detailed budget as part of the application when instructed by GBT, which will **undergo Fair Market Value (FMV) assessment.**
- Budgets must be developed based on activities, services and consumable supplies directly related to the project.
- Budget should consider **any overhead or GBT-required adverse event reporting** which may be required.

- GBT can support a maximum overhead rate of up to the NIH published rate.
- The overhead rate is only applicable to total direct study costs and will not be paid on indirect study costs.
- If your institution's overhead rate exceeds NIH rate, GBT will require a copy of the exemption letter.

Applicant requirements

- Must be available after September 30, 2021 for at least one (1) hour to answer questions from the review committee at GBT
- Must have appropriate scientific training, expertise and experience in implementation of clinical research or real-world evidence studies, including study research design, study conduct, analysis, and publication
- Must be able to implement and conduct the research within their health system
- Must be eligible to conduct research with industry support
- Must be willing to adhere to GBT's pharmacovigilance reporting requirements (if applicable)

Research expectations

- Research is to be implemented and expected to **be completed within twenty-four (24) months** from study initiation
- Applicants receiving grants are expected to **submit the results of their research to a peer-reviewed journal within six (6) months** of study completion for publication
- Proposals **must be** submitted and conducted in accordance with local regulatory, legal, and ethical guidelines

Submissions

All submissions will take place at the following GBT ESR web portal: https://www.cybergrants.com/gbt/esr_concept

Questions

Please contact your local GBT Medical Science Liaison. You may also email esr.gbt@gbt.com with any questions that you have.